TY - JOUR
T1 - The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature
AU - Visser, Marlieke
AU - Paulus, Walter J.
AU - Vermeulen, Mechteld A. R.
AU - Richir, Milan C.
AU - Davids, Mariska
AU - Wisselink, Willem
AU - de Mol, Bas A. J. M.
AU - van Leeuwen, Paul A. M.
PY - 2010
Y1 - 2010
N2 - Nitric oxide (NO) is formed from arginine by the enzyme nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) can inhibit NO production by competing with arginine for NOS binding. Therefore, the net amount of NO might be indicated by the arginine/ADMA ratio. In turn, arginine can be metabolized by the enzyme arginase, and ADMA by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). While ADMA has been implicated as a cardiovascular risk factor, arginine supplementation has been indicated as a treatment in cardiac diseases. This review discusses the roles of ADMA and arginine in the failing heart and its vasculature. Furthermore, it proposes nutritional therapies to improve NO availability
AB - Nitric oxide (NO) is formed from arginine by the enzyme nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) can inhibit NO production by competing with arginine for NOS binding. Therefore, the net amount of NO might be indicated by the arginine/ADMA ratio. In turn, arginine can be metabolized by the enzyme arginase, and ADMA by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). While ADMA has been implicated as a cardiovascular risk factor, arginine supplementation has been indicated as a treatment in cardiac diseases. This review discusses the roles of ADMA and arginine in the failing heart and its vasculature. Furthermore, it proposes nutritional therapies to improve NO availability
U2 - https://doi.org/10.1093/eurjhf/hfq158
DO - https://doi.org/10.1093/eurjhf/hfq158
M3 - Review article
C2 - 20923854
SN - 1388-9842
VL - 12
SP - 1274
EP - 1281
JO - European journal of heart failure
JF - European journal of heart failure
IS - 12
ER -